Dimerix is a clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix’s lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200. This study has repurposing of existing molecules at its core, and upon successful results from this study, Dimerix Bioscience was established as a private company in 2004, based on technology developed at the University of Western Australia, known as Receptor-Heteromer Investigation Technology (HIT)
Dimerix Bioscience underwent conversion to a public unlisted company in June 2014 and in July 2015 became a wholly owned subsidiary of Sun Biomedical Limited through a reverse takeover. Sun Biomedical’s name was changed to Dimerix Limited in November 2015.